NPPB and hydrops fetalis: Sacubitril/valsartan caused a 20% reduction in cardiovascular (CV) death and a 21% reduction in hospitalizations for HF (HHF) compared to enalapril in symptomatic HFrEF patients with left ventricular ejection fraction (LVEF) ≤40% (subsequently amended to ≤35%) and high BNP/NT-proBNP.